Literature DB >> 12091858

Time course to hypothyroidism after fixed-dose radioablation therapy of Graves' disease in children.

Todd D Nebesio1, Aslam R Siddiqui, Ora H Pescovitz, Erica A Eugster.   

Abstract

OBJECTIVE: To characterize the development of hypothyroidism in pediatric patients who receive a fixed dose of radioactive iodine (RAI). STUDY
DESIGN: Medical records of children treated with fixed-dose RAI for Graves'disease between 1993 and 2001 were reviewed. Multiple variables including sex, age, thyroid hormone levels, thyroid-stimulating immunoglobulin titer, antithyroid medication use, and 24-hour radioiodine uptake were investigated as possible predictive factors for the development of hypothyroidism after treatment. All patients received RAI at a dose of between 13.8 and 15.6 mCi (average, 14.7 mCi; SD, 0.5).
RESULTS: Permanent hypothyroidism developed in all 40 patients, although a second dose of RAI was required in one case. The average time to hypothyroidism was 77 days (SD, 32), with a range of 28 to 194 days; 75% of the patients were diagnosed with hypothyroidism between 40 and 90 days. RAI treatment was ineffective in an additional patient, who required subtotal thyroidectomy.
CONCLUSIONS: We conclude that a fixed dose of RAI is effective therapy in nearly all pediatric patients with Graves'disease. Factors predicting the time course to hypothyroidism were not identified.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12091858     DOI: 10.1067/mpd.2002.125494

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  16 in total

Review 1.  Radioiodine treatment for pediatric hyperthyroid Grave's disease.

Authors:  Ma Chao; Xie Jiawei; Wang Guoming; Liu Jianbin; Liu Wanxia; Al Driedger; Zuo Shuyao; Zhang Qin
Journal:  Eur J Pediatr       Date:  2009-05-07       Impact factor: 3.183

Review 2.  The treatment of Graves' disease in children and adolescents.

Authors:  Hae Sang Lee; Jin Soon Hwang
Journal:  Ann Pediatr Endocrinol Metab       Date:  2014-09-30

Review 3.  Controversies in the management of Graves' disease in children.

Authors:  S A Rivkees
Journal:  J Endocrinol Invest       Date:  2016-05-06       Impact factor: 4.256

4.  Clinical Cerenkov luminescence imaging of (18)F-FDG.

Authors:  Daniel L J Thorek; Christopher C Riedl; Jan Grimm
Journal:  J Nucl Med       Date:  2013-09-27       Impact factor: 10.057

5.  Success rate of radioactive iodine treatment for children and adolescent with hyperthyroidism.

Authors:  S Namwongprom; P Dejkhamron; K Unachak
Journal:  J Endocrinol Invest       Date:  2020-06-24       Impact factor: 4.256

6.  The Efficacy and Short- and Long-Term Side Effects of Radioactive Iodine Treatment in Pediatric Graves' Disease: A Systematic Review.

Authors:  Sarah L Lutterman; Nitash Zwaveling-Soonawala; Hein J Verberne; Frederik A Verburg; A S Paul van Trotsenburg; Christiaan F Mooij
Journal:  Eur Thyroid J       Date:  2021-07-12

Review 7.  Juvenile thyrotoxicosis; can we do better?

Authors:  G Birrell; T Cheetham
Journal:  Arch Dis Child       Date:  2004-08       Impact factor: 3.791

8.  Myopathy Associated with Acute Hypothyroidism following Radioiodine Therapy for Graves Disease in an Adolescent.

Authors:  Valeria C Benavides; Scott A Rivkees
Journal:  Int J Pediatr Endocrinol       Date:  2010-09-14

9.  Prediction of post-treatment hypothyroidism using changes in thyroid volume after radioactive iodine therapy in adolescent patients with Graves' disease.

Authors:  Nobuhiro Nakatake; Shuji Fukata; Junichi Tajiri
Journal:  Int J Pediatr Endocrinol       Date:  2011-11-07

10.  Clinical experience with radioactive iodine in the treatment of childhood and adolescent Graves' disease.

Authors:  Adriano N Cury; Verônica T Meira; Osmar Monte; Marília Marone; Nilza M Scalissi; Cristiane Kochi; Luís E P Calliari; Carlos A Longui
Journal:  Endocr Connect       Date:  2012-12-05       Impact factor: 3.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.